Table 1 Clinical and pathologic characteristics of patients and lesions in training and validation set
Training Set | Validation Set | |||||
|---|---|---|---|---|---|---|
Variable | Malignant nodules | Benign nodules | P Value | Malignant nodules | Benign nodules | P Value |
No.of lesions | 188 | 97 | 85 | 37 | ||
Median age (y) | 53(46–59) | 53(46–59) | .929 | 51(47–58) | 51(46–55) | .690 |
Sex | .531 | .624 | ||||
Male | 59(31.4) | 34(35.1) | 35(41.2) | 17(45.9) | ||
Female | 129(68.6) | 63(64.9) | 50(58.8) | 20(54.1) | ||
Smoking history | .617 | .039 | ||||
No | 152(80.9) | 76(78.4) | 66(77.6) | 22(59.5) | ||
Yes | 36(19.1) | 21(21.6) | 19(22.4) | 15(40.5) | ||
Family history of cancer | .408 | .126 | ||||
No | 160(85.1) | 86(88.7) | 72(84.7) | 35(94.6) | ||
Yes | 28(14.9) | 11(11.3) | 13(15.3) | 2(5.4) | ||
Biomarker positivea | ||||||
CEA positive(%)n = 300 | 24.3(34/140) | 13.4(9/67) | .072 | 18.5(12/65) | 17.9(5/28) | .945 |
NSE positive(%)n = 271 | 9.2(12/130) | 11.5(7/61) | .629 | 3.4(2/58) | 9.1(2/22) | .301 |
CYFRA21-1 positive(%)n = 297 | 25.4(35/138) | 40.9(27/66) | .024 | 24.6(16/65) | 28.6(8/28) | .689 |
SCC positive(%)n = 300 | 5.7(8/140) | 4.5(3/67) | .711 | 6.2(4/65) | 3.6(1/28) | .613 |